Age-dependent metabolic dysregulation in cancer and Alzheimer’s disease

Biogerontology

Volumn 15, Issue 6, 2014, Pages 559-577

  Harris, Richard A ^a   Tindale, Lauren ^a   Cumming, Robert C ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Aerobic glycolysis; Alzheimer s disease; Cancer; Metabolism; Mitochondria; Neurodegeneration; Oxidative phosphorylation; Warburg effect

Indexed keywords

GLUCOSE TRANSPORTER; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; OXYGEN; PEPTIDYLPROLYL ISOMERASE PIN1; PYRUVATE KINASE; HYPOXIA INDUCIBLE FACTOR 1; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE;

AGING; ALZHEIMER DISEASE; BIOSYNTHESIS; BRAIN METABOLISM; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; COGNITION; COMORBIDITY; GLYCOLYSIS; HUMAN; MACROMOLECULE; METABOLIC REGULATION; NEOPLASM; NERVE CELL PLASTICITY; NERVE DEGENERATION; OXIDATIVE PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; AEROBIC METABOLISM; AGED; BRAIN; METABOLISM; NEOPLASMS; NUCLEAR REPROGRAMMING; RISK FACTOR;

AEROBIOSIS; AGED; AGING; ALZHEIMER DISEASE; BRAIN; CELLULAR REPROGRAMMING; COMORBIDITY; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOLYSIS; HEXOKINASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; L-LACTATE DEHYDROGENASE; NEOPLASMS; NERVE DEGENERATION; OXIDATIVE PHOSPHORYLATION; PEPTIDYLPROLYL ISOMERASE; PYRUVATE KINASE; RISK FACTORS;

EID: 84916634296     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-014-9534-z     Document Type: Review

References (169)

1. Aizenstein HJ, Nebes RD, Saxton JA et al (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509–1517. doi:10.1001/archneur.65.11.1509
2. Anastasiou D, Poulogiannis G, Asara JM et al (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334:1278–1283. doi:10.1126/science.1211485
3. Arora KK, Pedersen PL (1988) Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem 263:17422–17428
4. Atchison FW, Means AR (2003) Spermatogonial depletion in adult pin1-deficient mice. Biol Reprod 69:1989–1997. doi:10.1095/biolreprod.103.020859
5. Atchison FW, Capel B, Means AR (2003) Pin1 regulates the timing of mammalian primordial germ cell proliferation. Dev Camb Engl 130:3579–3586
6. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V (2004) In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 377:347–355. doi:10.1042/BJ20031465
7. Baade PD, Fritschi L, Freedman DM (2007) Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology 28:16–20. doi:10.1159/000097851
8. Bagyinszky E, Youn YC, An S, Kim S (2014) The genetics of Alzheimer’s disease. Clin Interv Aging 9:535. doi:10.2147/CIA.S51571
9. Bao L, Kimzey A, Sauter G et al (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 164:1727–1737. doi:10.1016/S0002-9440(10)63731-5
10. Barros LF (2013) Metabolic signaling by lactate in the brain. Trends Neurosci 36:396–404. doi:10.1016/j.tins.2013.04.002
11. Barthel A, Okino ST, Liao J et al (1999) Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 274:20281–20286
12. Bateman RJ, Xiong C, Benzinger TLS et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804. doi:10.1056/NEJMoa1202753
13. Bauernfeind AL, Barks SK, Duka T et al (2013) Aerobic glycolysis in the primate brain: reconsidering the implications for growth and maintenance. Brain Struct Funct. doi:10.1007/s00429-013-0662-z
14. Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293–299
15. Benzinger TLS, Blazey T, Jack CR Jr et al (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA 110:E4502–E4509. doi:10.1073/pnas.1317918110
16. Birsoy K, Possemato R, Lorbeer FK et al (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508:108–112. doi:10.1038/nature13110
17. Boado RJ, Wang L, Pardridge WM (1994) Enhanced expression of the blood-brain barrier GLUT1 glucose transporter gene by brain-derived factors. Brain Res Mol Brain Res 22:259–267
18. Bolaños JP, Almeida A, Moncada S (2010) Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 35:145–149. doi:10.1016/j.tibs.2009.10.006
19. Bos R, van Der Hoeven JJM, van Der Wall E et al (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol Off J Am Soc Clin Oncol 20:379–387
20. Boyle PJ, Scott JC, Krentz AJ et al (1994) Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest 93:529–535. doi:10.1172/JCI117003
21. Braidy N, Guillemin GJ, Mansour H et al (2011) Age related changes in nad+ metabolism oxidative stress and sirt1 activity in wistar rats. PLoS ONE. doi:10.1371/journal.pone.0019194
22. Brown RS, Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 72:2979–2985
23. Burns A, Tomlinson B, Mann DMA (1997) Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11(205–242), 1968, 7. 331–356. Int J Geriatr Psychiatry 12:785–790. doi:10.1002/(SICI)1099-1166(199708)12:8<785:AID-GPS642>3.0.CO;2-F
24. Bustamante E, Pedersen PL (1977) High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 74:3735–3739
25. Bustamante E, Pedersen PL (1980) Mitochondrial hexokinase of rat hepatoma cells in culture: solubilization and kinetic properties. Biochemistry (Mosc) 19:4972–4977
26. Bustamante E, Morris HP, Pedersen PL (1981) Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256:8699–8704
27. Chen EI (2012) Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr 44:619–622. doi:10.1007/s10863-012-9465-9
28. Chiarugi A, Dölle C, Felici R, Ziegler M (2012) The NAD metabolome—a key determinant of cancer cell biology. Nat Rev Cancer 12:741–752. doi:10.1038/nrc3340
29. Christofk HR, Vander Heiden MG, Harris MH et al (2008a) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230–233. doi:10.1038/nature06734
30. Christofk HR, Vander Heiden MG, Wu N et al (2008b) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181–186. doi:10.1038/nature06667
31. Cottrell DA, Turnbull DM (2000) Mitochondria and ageing. Curr Opin Clin Nutr Metab Care 3:473–478
32. Cuadrado-Tejedor M, Vilariño M, Cabodevilla F et al (2011) Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer’s disease transgenic mice: an insight into the pathogenic effects of amyloid-β. J Alzheimers Dis JAD 23:195–206. doi:10.3233/JAD-2010-100966
33. David CJ, Chen M, Assanah M et al (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364–368. doi:10.1038/nature08697
34. Dawson DM, Goodfriend TL, Kaplan NO (1964) Lactic dehydrogenase: Functions of the two types rates of synthesis of the two major forms can be correlated with metabolic differentiation. Science 143:929–933
35. Dublois G, St-Pierre J, Giguere V (2013) The PGC-1ERR signaling axis in cancer. Oncogene 32:3483–3490
36. Demetrius L (1997) Directionality principles in thermodynamics and evolution. Proc Natl Acad Sci USA 94:3491–3498
37. Demetrius LA, Simon DK (2012) An inverse-Warburg effect and the origin of Alzheimer’s disease. Biogerontology 13:583–594. doi:10.1007/s10522-012-9403-6
38. Demetrius LA, Simon DK (2013) The inverse association of cancer and Alzheimer’s: a bioenergetic mechanism. J R Soc Interface R Soc 10:20130006. doi:10.1098/rsif.2013.0006
39. DeSouky AL (1992) The relationship between cancer and Alzheimer’s disease. J Am Geriatr Soc 40:1075–1076
40. Dienel GA (2012) Brain lactate metabolism: the discoveries and the controversies. J Cereb Blood Flow Metab 32:1107–1138. doi:10.1038/jcbfm.2011.175
41. Doherty JR, Cleveland JL (2013) Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123:3685–3692. doi:10.1172/JCI69741
42. Dos Santos JM, Benite-Ribeiro SA, Queiroz G, Duarte JA (2012) The effect of age on glucose uptake and GLUT1 and GLUT4 expression in rat skeletal muscle. Cell Biochem Funct 30:191–197. doi:10.1002/cbf.1834
43. Driver JA, Beiser A, Au R et al (2012) Inverse association between cancer and Alzheimer’s disease: results from the Framingham heart study. BMJ 344:e1442–e1442. doi:10.1136/bmj.e1442
44. El Mjiyad N, Caro-Maldonado A, Ramírez-Peinado S, Muñoz-Pinedo C (2011) Sugar-free approaches to cancer cell killing. Oncogene 30:253–264. doi:10.1038/onc.2010.466
45. Fois AF, Wotton CJ, Yeates D et al (2010) Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry 81:215–221. doi:10.1136/jnnp.2009.175463
46. Fox PT, Raichle ME, Mintun MA, Dence C (1988) Nonoxidative glucose consumption during focal physiologic neural activity. Science 241:462–464
47. Freedman DM, Travis LB, Gridley G, Kuncl RW (2005) Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 25:176–180. doi:10.1159/000087447
48. Friedland RP, Jagust WJ, Huesman RH et al (1989) Regional cerebral glucose transport and utilization in Alzheimer’s disease. Neurology 39:1427–1434
49. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899. doi:10.1038/nrc1478
50. Giang A-H, Raymond T, Brookes P et al (2013) Mitochondrial dysfunction and permeability transition in osteosarcoma cells showing the Warburg effect. J Biol Chem doi:10.1074/jbc.M113.507129
51. Gomes AP, Price NL, Ling AJY et al (2013) Declining NAD + induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155:1624–1638. doi:10.1016/j.cell.2013.11.037
52. Gómez-Isla T, Price JL, McKeel DW Jr et al (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci Off J Soc Neurosci 16:4491–4500
53. Gottschalk S, Anderson N, Hainz C et al (2004) Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res Off J Am Assoc Cancer Res 10:6661–6668. doi:10.1158/1078-0432.CCR-04-0039
54. Goyal MS, Hawrylycz M, Miller JA et al (2014) Aerobic glycolysis in the human brain is associated with development and neotenous gene expression. Cell Metab 19:49–57. doi:10.1016/j.cmet.2013.11.020
55. Hagen TM, Yowe DL, Bartholomew JC et al (1997) Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci 94:3064–3069
56. Hamanaka RB, Chandel NS (2010) Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci 35:505–513. doi:10.1016/j.tibs.2010.04.002
57. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185
58. Harman D (1972) The biologic clock: the mitochondria? J Am Geriatr Soc 20:145–147
59. Harr SD, Simonian NA, Hyman BT (1995) Functional alterations in Alzheimer’s disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol 54:38–41
60. Hayflick L (2007) Biological aging is no longer an unsolved problem. Ann NY Acad Sci 1100:1–13
61. Hitosugi T, Kang S, Vander Heiden MG et al (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2:ra73. doi:10.1126/scisignal.2000431
62. Hoeijmakers JHJ (2009) DNA damage, aging, and cancer. N Engl J Med 361:1475–1485. doi:10.1056/NEJMra0804615
63. Hubbi ME, Hu H, Kshitiz et al (2013) Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem 288:20768–20775. doi:10.1074/jbc.M113.476903
64. Hume DA, Weidemann MJ (1979) Role and regulation of glucose metabolism in proliferating cells. J Natl Cancer Inst 62:3–8
65. Imtiaz B, Tolppanen A-M, Kivipelto M, Soininen H (2014) Future directions in Alzheimer’s disease from risk factors to prevention. Biochem Pharmacol 88:661–670. doi:10.1016/j.bcp.2014.01.003
66. Jagust WJ, Seab JP, Huesman RH et al (1991) Diminished glucose transport in Alzheimer’s disease: dynamic PET studies. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 11:323–330. doi:10.1038/jcbfm.1991.65
67. Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509. doi:10.1002/ana.410170514
68. Jiang BH, Agani F, Passaniti A, Semenza GL (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328–5335
69. Johnson SC, Christian BT, Okonkwo OC et al (2014) Amyloid burden and neural function in people at risk for Alzheimer’s Disease. Neurobiol Aging 35:576–584. doi:10.1016/j.neurobiolaging.2013.09.028
70. Jurica MS, Mesecar A, Heath PJ et al (1998) The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Struct Lond Engl 1993 6:195–210
71. Kasischke KA, Vishwasrao HD, Fisher PJ et al (2004) Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 305:99–103. doi:10.1126/science.1096485
72. Le A, Cooper CR, Gouw AM et al (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107:2037–2042. doi:10.1073/pnas.0914433107
73. Lee TH, Tun-Kyi A, Shi R et al (2009) Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol 11:97–105. doi:10.1038/ncb1818
74. Lee TH, Pastorino L, Lu KP (2011) Peptidyl-prolyl cis–trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med 13:e21. doi:10.1017/S1462399411001906
75. Lim J-H, Lee Y-M, Chun Y-S et al (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. Mol Cell 38:864–878. doi:10.1016/j.molcel.2010.05.023
76. Liou Y-C, Ryo A, Huang H-K et al (2002) Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 99:1335–1340. doi:10.1073/pnas.032404099
77. Liou Y-C, Sun A, Ryo A et al (2003) Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424:556–561. doi:10.1038/nature01832
78. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B (2010) Understanding the “lethal” drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 10:537–542
79. Liu Y, Liu F, Iqbal K et al (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582:359–364. doi:10.1016/j.febslet.2007.12.035
80. Liu Y, Cao Y, Zhang W et al (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11:1672–1682. doi:10.1158/1535-7163.MCT-12-0131
81. Lu KP (2004) Pinning down cell signaling, cancer and Alzheimer’s disease. Trends Biochem Sci 29:200–209. doi:10.1016/j.tibs.2004.02.002
82. Lu KP, Zhou XZ (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8:904–916. doi:10.1038/nrm2261
83. Lu PJ, Wulf G, Zhou XZ et al (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784–788. doi:10.1038/21650
84. Lu C-W, Lin S-C, Chen K-F et al (2008) Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 283:28106–28114. doi:10.1074/jbc.M803508200
85. Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27:441–464. doi:10.1146/annurev-cellbio-092910-154237
86. Lustbader JW, Cirilli M, Lin C et al (2004) ABAD directly links Aß to mitochondrial toxicity in Alzheimer’s disease. Science 304:448–452. doi:10.1126/science.1091230
87. Lv L, Li D, Zhao D et al (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42:719–730. doi:10.1016/j.molcel.2011.04.025
88. Ma SL, Tang NLS, Tam CWC et al (2012) A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer’s disease. Neurobiol Aging 33:804–813. doi:10.1016/j.neurobiolaging.2010.05.018
89. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654–662. doi:10.1002/jcp.20166
90. Madsen PL, Hasselbalch SG, Hagemann LP et al (1995) Persistent resetting of the cerebral oxygen/glucose uptake ratio by brain activation: evidence obtained with the Kety-Schmidt technique. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 15:485–491. doi:10.1038/jcbfm.1995.60
91. Magistretti PJ (2006) Neuron-glia metabolic coupling and plasticity. J Exp Biol 209:2304–2311. doi:10.1242/jeb.02208
92. Magistretti PJ, Morrison JH, Shoemaker WJ et al (1981) Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. Proc Natl Acad Sci USA 78:6535–6539
93. Majewski N, Nogueira V, Bhaskar P et al (2004) Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16:819–830. doi:10.1016/j.molcel.2004.11.014
94. Manczak M, Anekonda TS, Henson E et al (2006) Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15:1437–1449. doi:10.1093/hmg/ddl066
95. Mani N, Khaibullina A, Krum JM, Rosenstein JM (2003) Activation of receptor-mediated angiogenesis and signaling pathways after VEGF administration in fetal rat CNS explants. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 23:1420–1429. doi:10.1097/01.WCB.0000090620.86921.9C
96. Marchesi VT (2012) Alzheimer’s disease 2012: the great amyloid gamble. Am J Pathol 180:1762–1767
97. Markert CL, Shaklee JB, Whitt GS (1975) Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function and regulation. Science 189:102–114
98. Massudi H, Grant R, Braidy N et al (2012) Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE. doi:10.1371/journal.pone.0042357
99. Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104–8109
100. Mayer D, Klimek F, Rempel A, Bannasch P (1997) Hexokinase expression in liver preneoplasia and neoplasia. Biochem Soc Trans 25:122–127
101. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15:300–308. doi:10.1016/j.semcancer.2005.04.009
102. McEwen BS, Reagan LP (2004) Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 490:13–24. doi:10.1016/j.ejphar.2004.02.041
103. McFate T, Mohyeldin A, Lu H et al (2008) Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283:22700–22708. doi:10.1074/jbc.M801765200
104. Minami Y, Yamamoto R, Nishikouri M et al (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247:429–434. doi:10.1007/s004150070171
105. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310:1500–1501. doi:10.1136/bmj.310.6993.1500
106. Mooradian AD, Chung HC, Shah GN (1997) GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 18:469–474
107. Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann NY Acad Sci 1147:180–195. doi:10.1196/annals.1427.007
108. Newington JT, Pitts A, Chien A et al (2011) Amyloid beta resistance in nerve cell lines is mediated by the warburg effect. PLoS ONE 6:e19191. doi:10.1371/journal.pone.0019191
109. Newington JT, Rappon T, Albers S et al (2012) Overexpression of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A in nerve cells confers resistance to amyloid beta and other toxins by decreasing mitochondrial respiration and ROS production. J Biol Chem. doi:10.1074/jbc.M112.366195
110. Newman LA, Korol DL, Gold PE (2011) Lactate produced by glycogenolysis in astrocytes regulates memory processing. PLoS ONE 6:e28427. doi:10.1371/journal.pone.0028427
111. Nolop KB, Rhodes CG, Brudin LH et al (1987) Glucose utilization in vivo by human pulmonary neoplasms. Cancer 60:2682–2689
112. Nowotny P, Bertelsen S, Hinrichs AL et al (2007) Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer’s disease. Neurosci Lett 419:15–17. doi:10.1016/j.neulet.2007.03.071
113. Okino ST, Chichester CH, Whitlock JP Jr (1998) Hypoxia-inducible mammalian gene expression analyzed in vivo at a TATA-driven promoter and at an initiator-driven promoter. J Biol Chem 273:23837–23843
114. Pastorino L, Sun A, Lu P-J et al (2006) The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440:528–534. doi:10.1038/nature04543
115. Pavlides S, Whitaker-Menezes D, Castello-Cros R et al (2009) The reverse Warburg effect, aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8:3894–4001
116. Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91:10625–10629
117. Petersen CAH, Alikhani N, Behbahani H et al (2008) The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci 105:13145–13150. doi:10.1073/pnas.0806192105
118. Pfeiffer T, Schuster S, Bonhoeffer S (2001) Cooperation and competition in the evolution of atp-producing pathways. Science 292:504–507. doi:10.1126/science.1058079
119. Piert M, Koeppe RA, Giordani B et al (1996) Diminished glucose transport and phosphorylation in Alzheimer’s disease determined by dynamic FDG-PET. J Nucl Med Off Publ Soc Nucl Med 37:201–208
120. Plun-Favreau H, Lewis PA, Hardy J et al (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6:e1001257. doi:10.1371/journal.pgen.1001257
121. Poli M, Gatta LB, Dominici R et al (2005) DNA sequence variations in the prolyl isomerase Pin1 gene and Alzheimer’s disease. Neurosci Lett 389:66–70. doi:10.1016/j.neulet.2005.07.027
122. Powers WJ, Videen TO, Markham J et al (2007) Selective defect of in vivo glycolysis in early Huntington’s disease striatum. Proc Natl Acad Sci U S A 104:2945–2949. doi:10.1073/pnas.0609833104
123. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368
124. Raichle ME, Posner JB, Plum F (1970) Cerebral blood flow during and after hyperventilation. Arch Neurol 23:394–403
125. Rempel A, Bannasch P, Mayer D (1994) Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219:660–668
126. Reske SN, Grillenberger KG, Glatting G et al (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med Off Publ Soc Nucl Med 38:1344–1348
127. Roe CM, Behrens MI, Xiong C et al (2005) Alzheimer disease and cancer. Neurology 64:895–898. doi:10.1212/01.WNL.0000152889.94785.51
128. Roe CM, Fitzpatrick AL, Xiong C et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74:106–112. doi:10.1212/WNL.0b013e3181c91873
129. Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005–3015. doi:10.1093/emboj/17.11.3005
130. Ryo A, Nakamura M, Wulf G et al (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3:793–801. doi:10.1038/ncb0901-793
131. Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642–22647
132. Schubert D (2005) Glucose metabolism and Alzheimer’s disease. Ageing Res Rev 4:240–257. doi:10.1016/j.arr.2005.02.003
133. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10:175–176. doi:10.1016/j.ccr.2006.08.015
134. Segat L, Pontillo A, Annoni G et al (2007) PIN1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Aging 28:69–74. doi:10.1016/j.neurobiolaging.2005.11.009
135. Selfridge, Eva J, Lu J, Swerdlow RH (2013) Role of mitochondrial homeostasis and dynamics in Alzheimer’s disease. Neurobiol Dis 51:3–12. doi:10.1016/j.nbd.2011.12.057
136. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51–56. doi:10.1016/j.gde.2009.10.009
137. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE (1991) Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci 88:5680–5684. doi:10.1073/pnas.88.13.5680
138. Settergren G, Lindblad BS, Persson B (1976) Cerebral blood flow and exchange of oxygen, glucose, ketone bodies, lactate, pyruvate and amino acids in infants. Acta Paediatr Scand 65:343–353
139. Simpson IA, Chundu KR, Davies-Hill T et al (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol 35:546–551. doi:10.1002/ana.410350507
140. Sørensen SA, Fenger K, Olsen JH (1999) Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer 86:1342–1346
141. Soucek T, Cumming R, Dargusch R et al (2003) The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39:43–56
142. Sperling RA, Jack CR Jr, Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med Med 3:111cm33. doi:10.1126/scitranslmed.3002609
143. Sun Q, Chen X, Ma J et al (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108:4129–4134. doi:10.1073/pnas.1014769108
144. Suzuki A, Stern SA, Bozdagi O et al (2011) Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 144:810–823. doi:10.1016/j.cell.2011.02.018
145. Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580. doi:10.1002/ana.410300410
146. Tillement L, Lecanu L, Papadopoulos V (2011) Further evidence on mitochondrial targeting of β-amyloid and specificity of β-amyloid-induced mitotoxicity in neurons. Neurodegener Dis 8:331–344. doi:10.1159/000323264
147. Trifunovic A, Wredenberg A, Falkenberg M et al (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429:417–423. doi:10.1038/nature02517
148. Trifunovic A, Hansson A, Wredenberg A et al (2005) Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci USA 102:17993–17998. doi:10.1073/pnas.0508886102
149. Trounce I, Byrne E, Marzuki S (1989) Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet 1:637–639
150. Vaishnavi SN, Vlassenko AG, Rundle MM et al (2010) Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci 107(41):17757–17762. doi:10.1073/pnas.1010459107
151. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52:395–398
152. Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12:357–367. doi:10.1016/S1474-4422(13)70044-9
153. Vlassenko AG, Rundle MM, Mintun MA (2006) Human brain glucose metabolism may evolve during activation: findings from a modified FDG PET paradigm. NeuroImage 33:1036–1041. doi:10.1016/j.neuroimage.2006.06.065
154. Vlassenko AG, Vaishnavi SN, Couture L et al (2010) Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc Natl Acad Sci 107:17763–17767. doi:10.1073/pnas.1010461107
155. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci 92:5510–5514
156. Wang J, Dickson DW, Trojanowski JQ, Lee VM-Y (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 158:328–337. doi:10.1006/exnr.1999.7085
157. Warburg O (1956) On the origin of cancer cells. Science 123:309–314
158. Weinberg F, Hamanaka R, Wheaton WW et al (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci 107:8788–8793. doi:10.1073/pnas.1003428107
159. Wijsman EM, Daw EW, Yu C-E et al (2004) Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet 75:398–409. doi:10.1086/423393
160. Wu LE, Gomes AP, Sinclair DA (2014) Geroncogenesis: metabolic changes during aging as a driver of tumorigenesis. Cancer Cell 25:12–19. doi:10.1016/j.ccr.2013.12.005
161. Wulf GM, Ryo A, Wulf GG et al (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20:3459–3472. doi:10.1093/emboj/20.13.3459
162. Yamada M, Sasaki H, Mimori Y et al (1999) Prevalence and risks of dementia in the Japanese population: RERF’s adult health study Hiroshima subjects. radiation effects research foundation. J Am Geriatr Soc 47:189–195
163. Yang W, Zheng Y, Xia Y et al (2012) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14:1295–1304. doi:10.1038/ncb2629
164. Yeung SJ, Pan J, Lee M-H (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer. Cell Mol Life Sci CMLS 65:3981–3999. doi:10.1007/s00018-008-8224-x
165. Zaid H, Abu-Hamad S, Israelson A et al (2005) The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ 12:751–760. doi:10.1038/sj.cdd.4401599
166. Zhang Z, Yan J, Chang Y et al (2011) Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem 18:4335–4343
167. Zhang H, Ma Q, Zhang Y, Xu H (2012) Proteolytic processing of Alzheimer’s β-amyloid precursor protein. J Neurochem 120(Suppl 1):9–21. doi:10.1111/j.1471-4159.2011.07519.x
168. Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835
169. Zhong L, D’Urso A, Toiber D et al (2010) The histone deacetylase sirt6 regulates glucose homeostasis via Hif1α. Cell 140:280–293. doi:10.1016/j.cell.2009.12.041